EU AI Proposal Impact on Video Surveillance Examined

Executive *******

*** **** ***** ************ impacts ** *** ******** include:

• ** ** *********** ** either "************" (******), "****-****" (mandatory ********** *****), *** "low ****" (******* ********** required)
• * ***** ******** ** that ** ******* ******** within *** **** ***** the *** ** ****** will ** ************* **, avoiding *** *****
• ****** *********** ** ****** "high ****" ********* ******** "mandatory" ********** ******** **** as ******** * "**** management ******", ********* ******** for "******** ****," ******** "human *********," *** ****
• ****** **** **** ** allowed ** *** **** recognition ** ****** ***** for ******* ******* ********, finding **** ********/*******, *** investigating "********* *******"
• *******/****** ********* **** "************ obligations" ********* ********** ** end *****.

********* **** ***** ******* fines ** *% ** global ******* ** €** million ($** *******), ********* is ******.

Background *** *******

***** ** ********** **** ** *****'* **** ** ******** and ****** ****** ** AI**** ******* ** ****. This ****-**** **** ************ from *** ** **** over ***** ****-**** ****:

*** ******** ** **** meant ** ****** "***** dignity, *******, ********, ********* and *** **** ** law *** ***** *********** rights" ** ******* *********** on **.

"2023 ** *** ********"

** ****** ****** **** first *********** ***** ** the ****; **** **** have *** ***** ** enact **. ***** ** no ******** ******** ****** ********* ***** *********** "*** *********** ** expected ** **** ** the ********, ********* ** people ********* *** ******* closely."

Major ********: ******** ** ******* ************* **

******** ** ******* *** those ******** ****** *** year ***** *** *** is ****** **** ** grandfathered **, ******** *** rules ****** ***** ** a "*********** ****** ** the ****** ** *******" of *** ** ******:

**** ***** ********** *** end-users *** ***** *** regulation ** ******* ** purchasing ******* **** **** released **** **** * year ***** *** ********** passed. **** **** ******* larger ********* *** **** many ******** "****-****" ** products *******, *************'* ****** *********** *******.** ********* ***** ********, of ******, ***** ***** products **** ** ************* highly *********.

Risk **********/"************" ** *********

***************** ** *** ***** into **** **********: "************" which ** ******, "****-****" which *** ********* ********** steps, *** "*** ****" where ******* ********** ** required.

** ***** ************ ************ are ********** ******** ** the "************" *****. *** only ** ********** ****** "unacceptable" ** "**-***** ****** scoring" ** ***********. **** means * ***** ********* provider ***** *** **** a ****** ** ****** that ***** ****** ********* to *** '**********' **** look, ** **** *** be ****** "**-***** ****** scoring."

Face *********** "****-****"

**** *********** ("****** ********* identification ** ******* *******") is ********** ** "****-****" due ** **** ******* potential "************** *******":

************ ** ****** *********** bias***** **** **** ******* are **** ******** *** ethnic ****** **** ***** home *********.

"High-Risk" ** ********** *********

*** ******** ******** ******** rules (******** *-**) *** "high-risk" ** ******* **********:

* "**** ********** ******" is ****** ** ******* possible ***** ********** *** product's ******** ** ********** "identification" *** "**********" ** risks ***** **** "********" of ********** ********. ***** must ** ********** ** reduced "******* ******** ****** and ***********", **** ******* mandated "*****" ** ******* launch ** ***** ** achieve ****.

********/******* **** ** ******* to "**** *** **** governance *********". **** ******** identifying "******** ******" ***** ensuring ******** *** "********, representative, **** ** ****** and ********." ******** ****** also *** "*****-**-***-*** ******** and *******-********** ********, **** as ****************, ** **********."

********* ************* *** *** high-risk ** ******** ***** "demonstrate **********" **** *** EU's ** ********** *** relevant ******** **** ***********.

"******-*******" ** ********* ** "ensure * ***** ** traceability" ********** *** ** system's "*********." ******** **** be ******** ** *** recording *****, ********* *********, input **** ***** *** to * *****, *** corresponding ***** ****. *** goal ** ** *** "situations **** *** ****** in *** ** ****** presenting * ****" ** fundamental ******.

"************ *** ********* ** information ** *****" ***** systems ***** ** "*********** by ************" ***** ******* intended *******, ******** ******, potentials *** ****** (***** risk "*********** ******"), *** performance ** ******** ********.

***** *********" ** ****-**** AI ******** ** ******** so ***** *** "***** understand *** ********** *** limitations" ** *** ****** and "*********" ********* *** AI's ****** ******* "****-*******" on *** ** ******. This ***** *** ****** must **** * ****** "override" ****** **** * "stop ******" ** "******* procedure."

****-**** ** ******* **** pay ******* ********* ** "accuracy, ********** *** *************": accuracy ******* "***** ** declared ** ************ ************" while ******* **** ** "resilient" ** "************ ***** party" ******* ********. ******* must ***** ******* ******** to ********** ******** **** ("data *********") *** ****** designed ** **** ******** ("adversarial ********") ***** **** flaws ** *** *****.

Role ** ********* *******: *************, *********, ************

*** ******** ****** ******* into ************* (** ***** representatives), ************, *********, *** end-users **** ********* **************** for ****:

• *************"***** **** *** ************** of *** ********** ** the ** ****** **** this **********" (*.*. ********* with *** ******** *****).
• ************* ******* ********** *********** and ****** ********* ************* is ** *****. **** must **** ****** "****** surveillance ***********" ** ******* that ******* * **** to "****** ** ****** or ** *** ********** of *********** ****** ** persons *** *********". ** an ******** ****** ** identified, ************* **** "******* an ********** ************** ***** is *********** ** *** Union."
• Distributors must ensure the "provider and the importer of the system, as applicable, have complied with the obligations set out in this Regulation", not sell products that do not meet conformity standards and inform authorities of risks to "health or safety or to the protection of fundamental rights of persons are concerned."
• Users must follow the provider's "instructions" as well as "Union or national law" and the required "human oversight measures". While following directions, users must ensure "input data is relevant" to the intended purpose of the system, must "monitor the operation" of a system, notifying the provider or distributor and suspending use if it presents a risk to "health or safety or to the protection of fundamental rights of persons are concerned". "Users of high-risk AI systems shall keep the logs" of that system "for a period that is appropriate" and "carry out a data protection impact assessment" as ******** ***** *** ****.

*** ***********, ********, **** or ***** *****-***** ***** be ********** * ********" if **** **** * system ** ******* ***** their ****, "****** *** intended *******" ** ******** system, ** **** "*********** modification" ** * ******.

Police *** ** ****-**** **** *********** *******

*** *********** ****** *** enforcement *** ** ****-**** face *********** ** ****** places ** ******** *********** (finding ******* ** ******* people), ******* ** ****** or ********* *******, *** identification ** *********** ** criminals *** ******* ******* laws:

*******, *********** ****** ** charge ** ******** **** constitutes ********** *** ** face *********** *** ** punishing ***** *** ******. For *******, ****** ********* *********** *** ** ***** surveillance ** ******* ******* as ****-********* *** ******'********* ***** *** ****** oppoisition**********, ***** ***** ****** both ********* ** *** real-time ****** *********** ** those ****** ******* ********* the ********.

Disclosure ******** *** *********** *********

***** *******/*********** ********* ******** disclosure ** ********, **** the *** ******* **** "natural ******* ****** ** notified **** **** *** exposed ** ** ******* recognition ****** ** * biometric ************** ******." ****** use ** ******* ********* is ********** ******** "****-****," but *** ******* ***.

*** *******, * ******** camera ********* ******* ******** are *****/*** **** ******** that ** ******** ******* along **** ******* ***** lump ****** **** "***, age, **** ******, *** colour, *******, ****** ****** or ****** ** ********* orientation."**** *** ***** ******* analytics** ** **** ******* of ***** ** ********** video ********* ******* **** see * ******* ******.

Fees ** ** *% ****** ******* ** €***

********* *** ********* *** law *** ****** ** a ******* **** ** 6% ** ****** ******* or €*** ($***) *** prohibited ********* ** ***-********** with ************ ** ****, 4% ** ****** ******* or €*** *** ***-********** with ***** *****, *** 2% ** ****** ******* or €*** *** ********* incomplete ** ********** ***********. Member ****** **** ** in ****** ** ********** violations ******* **** ********** Authorities ** ***** ******** national ********** ******.

Costs ********* *** ****-**** ** *********/*****

*** ** ********* **** each ******** ** ****-**** AI ******* **** **** to ***** ***** €*,*** to €*,*** ($*,***-$*,***) ** conform **** ****-**** ** system. *** ****-**** ** users, ****** ***** *** estimated ** ****** €*,*** to €*,*** ($*,***-$*,***) *** year *** ******.

**********

** *********, *** ******** surrounding ******** ** ******** will ******* *** ******** with ***** ******** ******** of ****-**** ******** *** deter *** ********.

** ***** ** *** overall ********** ******, *** larger ******** ** **** be *********** *** *** insurmountable. * *** ******** dollars *** **** *** face *** ****** ** not **** *** * company ********* **** $* ******* in ********* ****.

*******, *** **** *********** and *** ***** **** a ****** ** **** more *********** *** ***** likely ****** *** ******* availability ** "****-****" ** products ** *** **.